Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Net Cash Flow (2023 - 2025)

Immunocore Holdings' Net Cash Flow history spans 3 years, with the latest figure at -$29.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 57.61% year-over-year to -$29.3 million; the TTM value through Dec 2025 reached -$14.7 million, down 199.11%, while the annual FY2025 figure was -$14.7 million, 199.11% down from the prior year.
  • Net Cash Flow for Q4 2025 was -$29.3 million at Immunocore Holdings, down from $2.7 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $391.0 million in Q1 2024 and bottomed at -$327.7 million in Q2 2024.
  • The 3-year median for Net Cash Flow is $6.4 million (2023), against an average of $2.7 million.
  • The largest YoY upside for Net Cash Flow was 2758.78% in 2024 against a maximum downside of 3304.04% in 2024.
  • A 3-year view of Net Cash Flow shows it stood at -$12.3 million in 2023, then crashed by 461.17% to -$69.0 million in 2024, then soared by 57.61% to -$29.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Net Cash Flow are -$29.3 million (Q4 2025), $2.7 million (Q3 2025), and -$780000.0 (Q2 2025).